DOI: 10.36347/sjams.2023.v11i01.001

Pages: 1-6

Background: The COVID-19 pandemic, which has caused significant illness and mortality, has spread quickly throughout the world. Comorbidities coexisting with COVID-19 have been described as risk factors for adverse outcomes repeatedly. In order to determine if diabetic patients' prognoses are better or worse than those of non-diabetics, we sought to determine the prevalence of SARS CoV-2 in these individuals. Objective: The aim of this study was to determine the prevalence of SARS CoV-2 in individuals with diabetes mellitus and determine whether or not their prognosis differed from non-diabetics. Methods: A total of 654 COVID-19-positive patients were admitted to TMSS Medical College and Rafatullah Community Hospital in Bogura, Bangladesh, between June 1 and August 31, 2020. A purposive sampling technique was used to choose 341 patients with confirmed SARS-CoV-2 among them for this study. There will be no new investigative techniques, major danger, or financial load on the patient as a result of the study. This being a retrospective study informed consent was not taken. We investigated and compared their socio-demographic information, clinical traits, morbidities, lab results, and CT scan results. Results: The majority of the patients (75.4%) had at least one co-morbidity. They had the highest prevalence of DM (180; 52.8%), HTN (177; 51.9%), bronchial asthma (50; 14.7%), cardiac disease (35; 10.3%), and CKD (30; 8.8%). In comparison to younger patients, elderly individuals had a significantly higher prevalence of all comorbidities. Individual death rates for patients with diabetes, hypertension, heart disease, CKD, CVD, and COPD were all significantly higher than those of those without those comorbidities. Conclusion: In this study, we found that co-morbidities, a risk factor for the rapid progression of the Covid-19 symptoms, worsen the prognosis. Co-morbidity patients who are infected with Covid-19 should therefore receive extra care because they could get .....